Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

ABVC BioPharma, Inc. (ABVC)

0.75   0.02 (2.77%) 11-25 11:03
Open: 0.73 Pre. Close: 0.7298
High: 0.7578 Low: 0.73
Volume: 7,248 Market Cap: 24(M)

Technical analysis

as of: 2022-11-25 1:54:52 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 0.96     One year: 1.13
Support: Support1: 0.71    Support2: 0.65
Resistance: Resistance1: 0.82    Resistance2: 0.96
Pivot: 0.74
Moving Average: MA(5): 0.73     MA(20): 0.74
MA(100): 0.8     MA(250): 1.78
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 36     %D(3): 31.4
RSI: RSI(14): 49.8
52-week: High: 4.26  Low: 0.5
Average Vol(K): 3-Month: 48 (K)  10-Days: 12 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ABVC ] has closed below upper band by 38.0%. Bollinger Bands are 74.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.75 - 0.76 0.76 - 0.76
Low: 0.7 - 0.71 0.71 - 0.71
Close: 0.72 - 0.73 0.73 - 0.74

Company Description

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

Headline News

Thu, 17 Nov 2022
ABVC BioPharma Announces Phase II Vitargus Study Protocol Received Thai FDA Approval - ABVC BioPharma (NASDAQ:ABVC) - Benzinga

Thu, 17 Nov 2022
ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval - Yahoo Finance

Wed, 16 Nov 2022
Maxim Downgrades ABVC Biopharma to Hold From Buy -

Tue, 15 Nov 2022
ABVC Biopharma Earnings, Revenue Beat in Q3 By -

Mon, 14 Nov 2022
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results - Yahoo Finance

Mon, 07 Nov 2022
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD) - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 33 (M)
% Held by Insiders 1.706e+007 (%)
% Held by Institutions 40.2 (%)
Shares Short 23 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.841e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -5
Return on Assets (ttm) 372.8
Return on Equity (ttm) -100.9
Qtrly Rev. Growth 343000
Gross Profit (p.s.) -212.23
Sales Per Share -1043.56
EBITDA (p.s.) 1.29893e+006
Qtrly Earnings Growth -0.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow -9 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 1.12

Stock Dividends

Dividend 0
Forward Dividend 16360
Dividend Yield 0%
Dividend Pay Date 2019-05-07
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.